Clinical Trial

A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects

Completed Phase 3
View on ClinicalTrials.gov →
Summary
This study will examine comparative bioavailability of single dose of a fixed dose combination (FDC) of extended release Torsemide and Spironolactone given with or without food in healthy adult subjects.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-27; most recent amendment 2026-03-05.
Status change: Recruiting → Completed 2026-03-05
Trial Details
NCT Number NCT07043634
Lead Sponsor Sarfez Pharmaceuticals, Inc.
Conditions Bioavailability Heathy Volunteers
Enrollment 24 participants
Start Date 2025-06-15
Primary Completion 2025-12-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-06